Updates in HER2+ Early and Metastatic Breast Cancer - Episode 12

Options for Third- and Further-Line Treatment of HER2+ mBC

, , ,

Dr Debu Tripathy explains the treatment options for patients with HER2+ metastatic breast cancer in the third-line and later-line settings, including combination tucatinib/trastuzumab/capecitabine.

EP. 1: Incidence and Typical Prognosis of HER2+ Early Breast Cancer
EP. 2: Neoadjuvant Treatment of HER2+ Early Breast Cancer
EP. 3: De-Escalation Approaches in Patients with HER2+ Early Breast Cancer
EP. 4: Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer
EP. 5: Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer
EP. 6: Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)
EP. 7: Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer
EP. 8: Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer
EP. 9: Data Updates in Adjuvant HER2+ Early Breast Cancer from SABCS 2022
EP. 10: HER2+ mBC: First-Line Treatment Regimens
EP. 11: Second-Line Treatment of HER2+ mBC and Recent Data Updates
Now Viewing
EP. 12: Options for Third- and Further-Line Treatment of HER2+ mBC
EP. 13: Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC
EP. 14: Emerging Data and Investigational Agents in HER2+ mBC
EP. 15: Unmet Needs and the Future of HER2+ Breast Cancer Treatment